Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) is investing $55 million across its sites in North America & Asia, to expand its API manufacturing capabilities and capacities. Part of this investment will go into new, multi-purpose plants, with more than 270kL of total capacity, to support the current pipeline of approximately 80 late-stage programs PPS is currently assisting partners with. PPS will also expand its potency footprint (new Occupa...